期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

治疗多发性骨髓瘤新药——卡非佐米 被引量：6

下载PDF
导出
摘要 卡非佐米为四肽蛋白酶体抑制药,靶向蛋白酶体的糜蛋白酶样活性位点,用于治疗先前接受过包括硼替佐米和免疫调节药治疗并证实在最近期治疗完成的60 d或60 d内疾病进展的多发性骨髓瘤。多个临床研究证实,卡非佐米单药或与其他药物联合治疗具有较强的抗多发性骨髓瘤作用,毒性作用小,尤其外周神经病变发生率较低,患者耐受性好,安全性高,临床可长期使用。该文通过检索国外文献,从药理学、药动学和临床研究等方面对其进行论述。
作者 韩梅 葛明
机构地区 开滦总医院药剂科 河北省唐山市同济医院药剂科
出处 《医药导报》 CAS 北大核心 2013年第9期1200-1202,共3页 Herald of Medicine
关键词 卡非佐米 蛋白酶体 骨髓瘤 多发性 药理学 药动学
分类号 R979.1 [医药卫生—药品] R96 [医药卫生—药理学]
  • 相关文献

参考文献16

  • 1OCIO E M,MATEOS M V,SAN-MIGUEL J F.Novel agents derived from the currently approved treatments for MM:novel proteasome inhibitors and novel IMIDs[J].Expert Opin Investig Drugs,2012,21(8):1075-1087.
  • 2MUJTABA T,DOU Q P.Advances in the understanding of mechanisms and therapeutic use of bortezomib[J].Discov Med,2011,12(67):471-480.
  • 3MIRABELLA A C,PLETNEV A A,DOWNEY S L,et al.Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib[J].Chem Biol,2011,18(5):608-618.
  • 4JAIN S,DITFENBACH C,ZAIN J,et al.Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma[J].Core Evid,2011,6(1):43-57.
  • 5HURCHLA M A,GARCIA-GOMEZ A,HORNICK M C,et al.The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects[J].Leukemia,2012,27(2):430-440.
  • 6DASMAHAPATRA G,LEMBERSKY D,SON M P,et al.Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo[J].Mol Cancer Ther,2011,10(9):1686-1697.
  • 7SACCO A,AUJAY M,MORGAN B,et al.Carfilzomibde-pendent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia[J].Clin Cancer Res,2011,17(7):1753-1764.
  • 8The Internet Drug Index.Kyprolis[EB/OL].[2012-07-25/2012-09-10].http://www.rxlist.com/kyprolis-drug.htm.
  • 9YANG J,WANG Z,FANG Y,et al.Pharmacokinetics,phar-macodynamics,metabolism,distribution,and excretion of carfilzomib in rats[J].Drug Metab Dispos,2011,39(10):1873-1882.
  • 10ALSINA M,TRUDEL S,FURMAN R R,et al.A phase 1 single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma[J].Clin Cancer Res,2012,18(17):4830-4840.

同被引文献49

  • 1刘艳丽,何文君,潘舒,吴亚利,许琼明,杨世林.艾迪注射液溶血性、刺激性、全身过敏性实验研究[J].中医药学报,2011,39(3):19-22. 被引量：9
  • 2饶敏,张淑玲,熊莉娟.蛋白酶体抑制剂MG132诱导肿瘤细胞凋亡机制的研究进展[J].医学分子生物学杂志,2005,2(4):298-301. 被引量：10
  • 3Groll M, Kim K B, Kairies N, et al. Crystal structure of epoxomicin: 20S proteasome reveals a molecular basis for selectivity of , β -epoxyketone proteasome inhibitors[J]. JAm Chem Soc, 2000, 122: 1237-1238.
  • 4Yang J, Wang Z, Fang Y, et al. Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats[J]. Drug Metab Dispos, 2011, 39: 1873-1882.
  • 5FDA. Carfilzomib [EB/OL]. [2012-10-08]. http: // www. accessdata, fda. gov/drugsatfda_docs/label/2012/ 2027141bl. pdf.
  • 6Alsina M, Trudel S, Furman R R, et al. A phase I single- agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma[J]. Clin Cane Res, 2012, 18(17): 4830-4840.
  • 7Kuhn D J, Chen Q, Voorhees P M, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin- proteasome pathway, against preclinical models of multiple myeloma[J]. Blood, 2007, 110(9): 3281-3290.
  • 8Yang J, Wang Z, Fang Y, et al. Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats[J]. Drug Metab Disp, 2011, 39(10): 1873-1882.
  • 9O'Connor O A, Stewart A K, Vallone M, et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies[J]. Clin Canc Res,2009, 15(22): 7085-7091.
  • 10Badros A Z, Vij R, Martin T, et al. Carfilzomib in multiple myeloma patients with renal impairment: pharrnacokinetics and safety[J]. Leukemia, 2013, 27(8): 1707-1714.

引证文献6

二级引证文献22

医药导报
2013年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部